Clinical trials: Hypercoagulable State
HeartMate II Pump Thrombosis
PREVENtion of HeartMate II Pump Thrombosis
The purpose of this study is to assess how often blood clots form in the FDA-approved HeartMate® II (HM II) Left Ventricular Assist Device (LVAD) and to identify risks related to clotting within the pump.
- Trial name
- PREVENT (NCT02158403)
- Testing
- Clinical Management Recommendations for reducing pump thrombosis
- Where
- 23 sites in United States
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Type 2 Diabetes Mellitus
Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy.
- Trial name
- NCT01865474
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 122 people
- Sponsor
- Dexa Medica Group
Sepsis, Venous Thromboembolism
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied.
- Conditions
- Sepsis, Venous Thromboembolism, Disseminated Intravascular Coagulation
- Trial name
- NCT06765681
- Testing
- Diagnosis of both VTE and sepsis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Bayer